Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

Cardiovascular result studies indicate diminished hospitalization expenses, while prolonged weight reduction advantages may lower obesity-related healthcare use, encompassing joint replacement procedures, sleep apnea interventions, and cancer screening expenditures
Semaglutide and related drugs now represent one of the fastest-growing classes of pharmaceuticals, with estimated sales in the tens of billions and projected growth over the coming decades
Employees using these medications may benefit from nutrition guidance and working with a Registered Dietitian, adequate protein intake, and strength training support (Reference)
doi: 10.1056/NEJMc2302677 50 EdwardsKLiXLingvayI
That usually means prioritizing protein and filling predictable micronutrient gaps with clinician-informed supplements that fit real life